SEC Form SC 13G filed by UroGen Pharma Ltd.
$URGN
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/11/2026 | $43.00 | Buy | Ladenburg Thalmann |
| 4/10/2026 | $40.00 | Buy | Jefferies |
| 8/19/2025 | $36.00 | Overweight | Piper Sandler |
| 6/16/2025 | $50.00 | Neutral → Buy | H.C. Wainwright |
| 5/22/2025 | Buy → Neutral | H.C. Wainwright | |
| 4/16/2025 | $23.00 | Sector Outperform | Scotiabank |
| 2/19/2025 | $31.00 | Buy | Ladenburg Thalmann |
| 8/22/2024 | $40.00 | Buy | Guggenheim |
Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolioTeva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has entered into a settlement and license agreement (the "Agreement"') with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals, USA, Inc. (collectively, "Teva"). This Agreement resolve
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026. Goldman Sachs 47th Annual Global Healthcare Conference Date / Time:June 10, 2026, at 8:40 AM ETFormat:Fireside chat and 1x1 investor meetingsLocation:Miami Beach, FLWebcast Link:here The webcast from the conference will also be available on UroGen's corporate website, under Events & Presentations. A replay will be available for approximately 90 days. About UroGen Pharm
PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.1, 97.9) durability of response (DOR) at six months by Kaplan-Meier estimate, in the ongoing Phase 3 UTOPIA trial of UGN-103 (mitomycin) for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The six-month results from UTOPIA are generally consistent with the 91.9% (95% CI: 86.9, 95.0) six-month DOR observed with ZUSDURI™ (mitomycin) for intravesical therapy in its pivotal ENVISION t
Ladenburg Thalmann resumed coverage of UroGen Pharma with a rating of Buy and set a new price target of $43.00
Jefferies initiated coverage of UroGen Pharma with a rating of Buy and set a new price target of $40.00
Piper Sandler initiated coverage of UroGen Pharma with a rating of Overweight and set a new price target of $36.00
4 - UroGen Pharma Ltd. (0001668243) (Issuer)
4 - UroGen Pharma Ltd. (0001668243) (Issuer)
4 - UroGen Pharma Ltd. (0001668243) (Issuer)
8-K - UroGen Pharma Ltd. (0001668243) (Filer)
SCHEDULE 13G - UroGen Pharma Ltd. (0001668243) (Subject)
10-Q - UroGen Pharma Ltd. (0001668243) (Filer)
Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. "Under Don's financial stewardship, we have strengthened our financial position and achieved significant milestones, which include multiple capital raises and investing in the potential commercial launch of UGN-102 for low-grade intermediate-risk non-musc
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen's commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution. David Lin brings to UroGen a wealth of experience garnered from a distinguished career in the pharmaceutical industry. Prior to joining U
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026JELMYTO achieved $21.7 million in revenue in Q1 2026, representing year-over-year growth of 7%Continued advancement of next-generation pipeline, UGN-103 on track for NDA submission in the second half of 2026; six-month durability data expected in mid-2026UroGen to host Key Opinion Leader (KOL) panel highlighting real-world experience with ZUSDURI at the American Urological Association (AUA) annual meeting on May 17th at 8:30 AM ETConference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., May
PRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2026 financial results on Wednesday, May 6th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroGen Pharma Ltd. UroGen
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecting the initial launch period ahead of the permanent J CodePermanent J Code for ZUSDURI became effective on January 1, 2026, streamlining reimbursement procedures and supporting broader patient accessJELMYTO® achieved net product sales of $94 million in 2025, representing year-over-year underlying demand sales growth of 7%Announced refinancing of existing term loan with Pharmakon Advisors that provides additional non-dilutive capital at more favorable termsCon
SC 13D/A - UroGen Pharma Ltd. (0001668243) (Subject)
SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)
SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)